CareDx, Inc (NASDAQ:CDNA) Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its holdings in CareDx, Inc (NASDAQ:CDNA - Free Report) by 29.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,141 shares of the company's stock after purchasing an additional 14,721 shares during the period. BNP Paribas Financial Markets owned approximately 0.12% of CareDx worth $1,373,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Sterling Capital Management LLC grew its holdings in shares of CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after purchasing an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after acquiring an additional 3,322 shares during the last quarter. Plato Investment Management Ltd lifted its stake in CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after acquiring an additional 1,370 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in CareDx by 41.5% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after acquiring an additional 2,742 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in CareDx in the fourth quarter worth approximately $208,000.

CareDx Price Performance

Shares of NASDAQ:CDNA traded down $0.16 during trading on Friday, hitting $16.95. 982,264 shares of the company were exchanged, compared to its average volume of 894,949. The stock has a market capitalization of $943.79 million, a P/E ratio of -6.28 and a beta of 2.27. CareDx, Inc has a 12-month low of $12.90 and a 12-month high of $34.84. The firm's 50 day moving average price is $17.48 and its 200-day moving average price is $20.71.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same quarter in the prior year, the firm earned ($0.03) EPS. CareDx's revenue for the quarter was up 17.6% on a year-over-year basis. As a group, equities research analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Stephens reiterated an "overweight" rating and issued a $40.00 price target on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. HC Wainwright reiterated a "neutral" rating and issued a $25.00 price target on shares of CareDx in a research note on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, CareDx currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

Insider Activity at CareDx

In other CareDx news, Director Peter Maag sold 13,281 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total value of $228,831.63. Following the transaction, the director now directly owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. The trade was a 4.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christine Cournoyer sold 16,700 shares of the business's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $14.13, for a total transaction of $235,971.00. Following the completion of the transaction, the director now directly owns 37,045 shares in the company, valued at $523,445.85. This represents a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,382 shares of company stock worth $934,509 in the last 90 days. 4.90% of the stock is owned by insiders.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.